Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals

Set Alert for Deals

Deal Watch: Genentech Expands Upon Arvinas PROTAC Collaboration

The Roche affiliate doubles the potential monetary value of partnership focused on PROTAC technology in a range of therapeutic areas. Cardinal sells off Chinese business for $1.2bn, while Novartis licenses Homology’s gene-editing technology.

Deals Business Strategies M & A
Advertisement

Deals

Set Alert for Deals

Latest From Deals

Celgene's Partnered Pipeline Delivers Successes And Setbacks

Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.

Deals Business Strategies

Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer

The German pharma signs collaboration to develop and commercialize larotrectinib and a follow-on, under a structure that enables Loxo to co-promote in the US and build commercial infrastructure.

Deals Cancer

J&J Deal Helps Zymeworks Continue Transformational Year

Vancouver biotech says $50m up front from Janssen reflects clinical validation of its antibody technology platforms. Firm also moved first proprietary candidate into clinic and netted $59m from an IPO in 2017.

Deals Platform Technologies

CNS Refresh: Boehringer's New Approach To Tricky Neuropsychiatry Diseases

Boehringer Ingelheim is seeking partners with early-stage, novel approaches to neuropsychiatry disorders under its strategy of applying "fresh thinking" to diseases of the central nervous system with high unmet need.

Neurology Business Strategies

Venture Funding Deals: From ADC To Y-mAbs, Capital Flows For New Platforms, Novel Approaches

October was an active fundraising month for both start-up biopharma companies and more established privately held firms, ranging from $3m for Appili's drug for anaerobic infections to $270m for Harmony's rare disease programs.

Financing Commercial

Sanofi Expands MS Portfolio With BTK Inhibitor From Principia

The French pharma adds the Phase I candidate to its Lemtrada follow-on for multiple sclerosis development, while Principia will use $40m in upfront cash to advance its orphan disease strategy.

Deals Neurology
See All
UsernamePublicRestriction

Register